COMMUNIQUÉS West-GlobeNewswire

Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
10/04/2024
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDT RNA delivery business progressing with new collaborations, potential new applications Partnering [...]
Kura Oncology to Participate in Stifel Targeted Oncology Forum
10/04/2024
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/04/2024
PALO ALTO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today [...]
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
10/04/2024
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity [...]
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
10/04/2024
Q1 2024 consolidated revenue of $16.2 million Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA 1 FY2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the [...]
Theratechnologies présente ses résultats financiers et fait le point sur ses activités commerciales pour le premier trimestre de l’exercice 2024
10/04/2024
Revenus consolidés de 16,2 millions de dollars au premier trimestre de 2024 Dégagement d’un BAIIA ajusté 1 allant de quasi stable à positif pour un troisième trimestre consécutif Prévisions de revenus pour l’exercice [...]
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
10/04/2024
CELEBRATION, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it has entered into a new credit [...]
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
10/04/2024
MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
BioPorto A/S Appoints Chief Legal Officer
10/04/2024
April 10, 2024 Announcement no. 8 BioPorto A/S Appoints Chief Legal Officer COPENHAGEN, DENMARK and BOSTON, MA, USA, April 10, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro [...]
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
10/04/2024
Vancouver, Canada, April 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery and development of novel [...]
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
10/04/2024
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, [...]
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
10/04/2024
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumab HB-200 program receives Priority Medicines (PRIME) designation from EMA NEW YORK and VIENNA, Austria [...]
Interactive Strength Inc. (Nasdaq: TRNR) to Exhibit CLMBR at FIBO Global Fitness, the World's Largest Trade Show for Fitness, Wellness and Health on April 11-14
10/04/2024
FIBO Global Fitness Expects to Have More Than 150,000 Visitors for the Trade Show in Cologne, Germany CLMBR is Receiving Significant Interest From International Boutique Fitness Operators and Gym Chains AUSTIN, TX, [...]
Immuron Travelan® sales continued strong growth
10/04/2024
Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcp Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia FYTD Mar 2024 AUD$2.8 million up 234% on [...]
Ouma Health reaches milestones in solving maternity care challenges for Managed Care Organizations
10/04/2024
Maternity telehealth platform identifies previously undiagnosed depression in 27% of pregnant & postpartum Medicaid members LOS ANGELES, April 10, 2024 (GLOBE NEWSWIRE) -- Ouma Health, a maternity telehealth company [...]
RadNet to Make its Second Acquisition in Houston, Texas
10/04/2024
LOS ANGELES, April 10, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces that it has signed a [...]
Medicines360 Appoints Erica Rogers to Board of Directors
10/04/2024
Rogers brings over 30 years of experience in the medical technology and healthcare sectors to Medicines360 SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Medicines360, a global mission-driven women's health company [...]
ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa
10/04/2024
VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoreceptor target cells in retinitis pigmentosa patients VG901, using ViGeneron’s proprietary next-generation [...]
EFA Technologies, pioneer in portable blood labs, enters Brazilian market after Anvisa approval of its portable RevDx device
10/04/2024
efa-technologies.com EFA also secures US $6.5 Million in funding, backed by existing investors and new partners Tel Aviv, Israel, 10 April 2024 - EFA Technologies, pioneers in portable blood labs, today announces the [...]

Pages